MetLife (NYSE: MET) director receives 273-share stock compensation grant

Rhea-AI Filing Summary

MetLife Inc director Daniel S. Glaser reported an acquisition of 273 shares of MetLife common stock on February 24, 2026 as a grant or award. The shares, valued at $75.34 per share, increased his direct holdings to 1,578 shares and were deferred under MetLife’s non-management director deferred compensation plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Glaser Daniel S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	273	$75.34	$21K

Holdings After Transaction: Common Stock — 1,578 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glaser Daniel S

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NY 10166

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A(1)		273	A	$75.34	1,578	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

Remarks:

	/s/ Taylor McInerney Jansen, Attorney-in-fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MetLife (MET) director Daniel S. Glaser report?

Daniel S. Glaser reported receiving 273 shares of MetLife common stock as a grant or award. The transaction occurred on February 24, 2026, and reflects non-management director compensation that is partially paid in stock under MetLife’s director compensation arrangements.

At what price was the MetLife (MET) stock grant to Daniel S. Glaser recorded?

The 273-share grant to Daniel S. Glaser was recorded at a price of $75.34 per share. This price is used for reporting and valuation of the director’s stock-based compensation under MetLife’s non-management director compensation arrangements.

How many MetLife (MET) shares does Daniel S. Glaser own after this Form 4 transaction?

After this transaction, Daniel S. Glaser is reported as directly owning 1,578 shares of MetLife common stock. This total includes the 273-share grant reported on February 24, 2026, as part of his non-management director compensation in stock.

How is MetLife (MET) non-management director compensation structured in this Form 4?

MetLife’s non-management director compensation includes paying a portion of retainer fees in MetLife common stock. In this case, Daniel S. Glaser received 273 shares as part of that program, which are treated as a grant or award of common stock.

Did Daniel S. Glaser defer his MetLife (MET) stock grant under a plan?

Yes. Daniel S. Glaser elected to defer receipt of the 273 MetLife common shares under the MetLife Deferred Compensation Plan for Non-Management Directors, according to the footnote, meaning the stock-based compensation is credited but actual receipt is deferred.

Is the MetLife (MET) Form 4 transaction a market purchase or a compensation award?

The Form 4 transaction is a compensation award, not a market purchase. It is coded as a grant, award, or other acquisition of 273 shares of MetLife common stock under the company’s non-management director compensation arrangements, rather than an open-market trade.